Immunotherapy drug nivolumab takes on rare childhood cancer
NCT ID NCT06622941
First seen Feb 04, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This phase 2 trial is testing the immunotherapy drug nivolumab in 23 people aged 1 year and older with advanced or recurrent rhabdoid tumors that have not responded to chemotherapy. The goal is to see if the drug can shrink tumors and improve survival. Participants receive nivolumab every two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Hyogo Prefectural Kobe Children's Hospital
RECRUITINGKobe, Hyōgo, Japan
-
Nagoya University Hospital
RECRUITINGNagoya, Aichi-ken, Japan
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, Japan
-
Osaka City General Hospital
RECRUITINGOsaka, Osaka, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab (a type of immunotherapy that helps the immune system fight cancer)
What this could lead to
If it works, this could offer a new treatment option for people with rhabdoid tumors that have not responded to chemotherapy.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.